The increase in revenue was driven by $4.57bn base revenue, representing a 6% growth and 9.3% on a currency-neutral basis.
In this quarter, the company’s global Covid-only testing revenues declined to $76m from $300m reported in the previous year.
The GAAP diluted earnings per share (EPS) for the quarter stood at $1.28, reflecting a 3% fall from $1.32 in the previous year’s quarter.
BD delivered diluted EPS of $2.66 in the third quarter of fiscal 2022, which ended on 30 June, reflecting a 16.7% increase from last year.
The company’s BD Medical segment reported $2.19bn revenues, a 4.7% growth from the same quarter of the previous year.
This growth is attributed to strong performance in Medication Delivery Solutions (MDS) and Pharmaceutical Systems (PS) business units.
The BD Life Sciences segment generated $1.31bn revenue, showing an 8.7% decrease over the year.
In the BD Interventional segment, $1.14bn revenue was generated, a 5.5% increase from the year-ago quarter.
BD chairman, CEO and president Tom Polen said: “Our BD2025 strategy continues to serve as our True North and has proven to be an effective, winning strategy as reflected in our continued strong performance, even amid a challenging macro environment.”
“Through our talented team’s focused execution and commitment to our purpose, we are advancing our Grow-Simplify-Empower initiatives, innovation pipeline and capital deployment strategy, which are all contributing to profitable growth.”
In this quarter, the company launched BD COR System in the US, and the CE marked BD MAX respiratory viral panel for Covid-19, Influenza A/B and Respiratory Syncytial Virus.
Last month, BD’s new molecular diagnostic combination test BD MAX Respiratory Viral Panel (RVP) received a CE-IVD mark.